{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:22:23Z","timestamp":1794352943340,"version":"4.9.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"DOI":"10.1038\/s41585-026-01179-y","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:19:57Z","timestamp":1785946797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrating clinically actionable biomarkers into bladder cancer care \u2014 recommendations from the International Bladder Cancer Group"],"prefix":"10.1038","author":[{"given":"Patrick J.","family":"Hensley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9361-2342","authenticated-orcid":false,"given":"Jeremy Y. C.","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-7200","authenticated-orcid":false,"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8775-503X","authenticated-orcid":false,"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bukavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-7343","authenticated-orcid":false,"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-8399","authenticated-orcid":false,"given":"Niyati","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6119-4043","authenticated-orcid":false,"given":"Wei Shen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2938-6627","authenticated-orcid":false,"given":"Hikmat A.","family":"Al-Ahmadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinity J.","family":"Bivalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-5293","authenticated-orcid":false,"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-9040","authenticated-orcid":false,"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3100-2810","authenticated-orcid":false,"given":"Amir","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max R.","family":"Kates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrinath R.","family":"Konety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet B.","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-2723","authenticated-orcid":false,"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1391-1378","authenticated-orcid":false,"given":"Maria Carmen","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Oualla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdana","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9928","authenticated-orcid":false,"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"1179_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41571-025-01095-x","volume":"23","author":"S Coca Membribes","year":"2026","unstructured":"Coca Membribes, S., Szabados, B. & Powles, T. Towards biomarker-driven therapies for urothelial carcinoma. Nat. Rev. Clin. Oncol. 23, 92\u2013106 (2026).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1179_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2026.06.012","author":"C Thibault","year":"2026","unstructured":"Thibault, C. et al. Molecular profiling of urothelial bladder cancer: bridging tumor biology and clinical decision-making. Eur. Urol. Oncol. https:\/\/doi.org\/10.1016\/j.euo.2026.06.012 (2026).","journal-title":"Eur. Urol. Oncol."},{"key":"1179_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.eururo.2019.01.031","volume":"76","author":"A Bessa","year":"2019","unstructured":"Bessa, A. et al. Consensus in bladder cancer research priorities between patients and healthcare professionals using a four-stage modified Delphi method. Eur. Urol. 76, 258\u2013259 (2019).","journal-title":"Eur. Urol."},{"key":"1179_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/bju.70206","author":"N Humayun-Zakaria","year":"2026","unstructured":"Humayun-Zakaria, N., Tura, B. J., van Hemelrijck, M. & Bryan, R. T. Aligning bladder cancer research with patient needs: an update on research priorities. BJU Int. https:\/\/doi.org\/10.1111\/bju.70206 (2026).","journal-title":"BJU Int."},{"key":"1179_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.eururo.2024.08.001","volume":"86","author":"R Li","year":"2024","unstructured":"Li, R. et al. Bladder-sparing therapy for Bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: international bladder cancer group recommendations for optimal sequencing and patient selection. Eur. Urol. 86, 516\u2013527 (2024).","journal-title":"Eur. Urol."},{"key":"1179_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.eururo.2025.03.017","volume":"89","author":"S Gupta","year":"2026","unstructured":"Gupta, S. et al. Bladder preservation strategies in muscle-invasive bladder cancer: recommendations from the international bladder cancer group. Eur. Urol. 89, 18\u201328 (2026).","journal-title":"Eur. Urol."},{"key":"1179_CR7","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1158\/1055-9965.EPI-13-0632","volume":"22","author":"MC Mir","year":"2013","unstructured":"Mir, M. C. et al. Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. Cancer Epidemiol. Biomarkers Prev. 22, 2241\u20132249 (2013).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"1179_CR8","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis, A. T., Lec, P. M., Chamie, K. & Mshs, M. D. Bladder cancer: a review. JAMA 324, 1980\u20131991 (2020).","journal-title":"JAMA"},{"key":"1179_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.euo.2024.01.011","volume":"7","author":"N Lobo","year":"2024","unstructured":"Lobo, N. et al. Association of age with non-muscle-invasive bladder cancer: unearthing a biological basis for epidemiological disparities? Eur. Urol. Oncol. 7, 1069\u20131079 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1179_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester, R. J. et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur. Urol. 79, 480\u2013488 (2021).","journal-title":"Eur. Urol."},{"key":"1179_CR11","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez, J. et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus calmette-guerin: the CUETO scoring model. J. Urol. 182, 2195\u20132203 (2009).","journal-title":"J. Urol."},{"key":"1179_CR12","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2011.1142","volume":"306","author":"ND Freedman","year":"2011","unstructured":"Freedman, N. D., Silverman, D. T., Hollenbeck, A. R., Schatzkin, A. & Abnet, C. C. Association between smoking and risk of bladder cancer among men and women. JAMA 306, 737\u2013745 (2011).","journal-title":"JAMA"},{"key":"1179_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00420-013-0916-3","volume":"87","author":"B Pesch","year":"2014","unstructured":"Pesch, B. et al. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. Int. Arch. Occup. Env. Health 87, 715\u2013724 (2014).","journal-title":"Int. Arch. Occup. Env. Health"},{"key":"1179_CR14","doi-asserted-by":"publisher","first-page":"djv223","DOI":"10.1093\/jnci\/djv223","volume":"107","author":"JD Figueroa","year":"2015","unstructured":"Figueroa, J. D. et al. Modification of occupational exposures on bladder cancer risk by common genetic polymorphisms. J. Natl Cancer Inst. 107, djv223 (2015).","journal-title":"J. Natl Cancer Inst."},{"key":"1179_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-85565-3","volume":"15","author":"S Li","year":"2025","unstructured":"Li, S., Gui, J., Karagas, M. R. & Passarelli, M. N. Transcriptome-wide association study identifies genes associated with bladder cancer risk. Sci. Rep. 15, 1390 (2025).","journal-title":"Sci. Rep."},{"key":"1179_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.eururo.2013.02.036","volume":"64","author":"CH Bangma","year":"2013","unstructured":"Bangma, C. H. et al. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur. Urol. 64, 41\u201347 (2013).","journal-title":"Eur. Urol."},{"key":"1179_CR17","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1097\/JU.0000000000002135","volume":"206","author":"JD Raman","year":"2021","unstructured":"Raman, J. D. et al. The diagnostic performance of CxBladder resolve, alone and in combination with other CxBladder tests, in the identification and priority evaluation of patients at risk for urothelial carcinoma. J. Urol. 206, 1380\u20131389 (2021).","journal-title":"J. Urol."},{"key":"1179_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/JU.0000000000003991","volume":"212","author":"Y Lotan","year":"2024","unstructured":"Lotan, Y. et al. A multicenter prospective randomized controlled trial comparing CxBladder triage to cystoscopy in patients with microhematuria: the safe testing of risk for asymptomatic microhematuria trial. J. Urol. 212, 41\u201351 (2024).","journal-title":"J. Urol."},{"key":"1179_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.eururo.2018.03.008","volume":"74","author":"WS Tan","year":"2018","unstructured":"Tan, W. S. et al. Who should be investigated for haematuria? Results of a contemporary prospective observational study of 3556 patients. Eur. Urol. 74, 10\u201314 (2018).","journal-title":"Eur. Urol."},{"key":"1179_CR20","doi-asserted-by":"publisher","first-page":"e218409","DOI":"10.1001\/jamanetworkopen.2021.8409","volume":"4","author":"S Waisbrod","year":"2021","unstructured":"Waisbrod, S. et al. Assessment of diagnostic yield of cystoscopy and computed tomographic urography for urinary tract cancers in patients evaluated for microhematuria: a systematic review and meta-analysis. JAMA Netw. Open. 4, e218409 (2021).","journal-title":"JAMA Netw. Open."},{"key":"1179_CR21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.eururo.2019.10.010","volume":"77","author":"I Jubber","year":"2020","unstructured":"Jubber, I. et al. Non-visible haematuria for the detection of bladder, upper tract, and kidney cancer: an updated systematic review and meta-analysis. Eur. Urol. 77, 583\u2013598 (2020).","journal-title":"Eur. Urol."},{"key":"1179_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/bju.14459","volume":"123","author":"WS Tan","year":"2019","unstructured":"Tan, W. S. et al. Does urinary cytology have a role in haematuria investigations? BJU Int. 123, 74\u201381 (2019).","journal-title":"BJU Int."},{"key":"1179_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/JU.0000000000004490","volume":"213","author":"DA Barocas","year":"2025","unstructured":"Barocas, D. A. et al. Updates to microhematuria: AUA\/SUFU guideline (2025). J. Urol. 213, 547\u2013557 (2025).","journal-title":"J. Urol."},{"key":"1179_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2340\/sju.v58.11142","volume":"58","author":"P-U Malmstr\u00f6m","year":"2023","unstructured":"Malmstr\u00f6m, P.-U. & Truls, G. Abandoning testing for asymptomatic microscopic haematuria in Sweden \u2013 a long-term follow-up. Scand. J. Urol. 58, 109\u2013114 (2023).","journal-title":"Scand. J. Urol."},{"key":"1179_CR25","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","volume":"6","author":"N Lobo","year":"2020","unstructured":"Lobo, N. et al. What is the significance of variant histology in urothelial carcinoma? Eur. Urol. Focus. 6, 653\u2013663 (2020).","journal-title":"Eur. Urol. Focus."},{"key":"1179_CR26","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1007\/s00345-019-02673-2","volume":"37","author":"A Brant","year":"2019","unstructured":"Brant, A. et al. Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer. World J. Urol. 37, 2683\u20132689 (2019).","journal-title":"World J. Urol."},{"key":"1179_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-023-01342-2","volume":"23","author":"H Wan","year":"2023","unstructured":"Wan, H. et al. Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer. BMC Urol. 23, 182 (2023).","journal-title":"BMC Urol."},{"key":"1179_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00345-012-0877-2","volume":"31","author":"M Cosentino","year":"2013","unstructured":"Cosentino, M. et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J. Urol. 31, 141\u2013145 (2013).","journal-title":"World J. Urol."},{"key":"1179_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","volume":"61","author":"BWG van Rhijn","year":"2012","unstructured":"van Rhijn, B. W. G. et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur. Urol. 61, 378\u2013384 (2012).","journal-title":"Eur. Urol."},{"key":"1179_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00345-019-02936-y","volume":"38","author":"M Kardoust Parizi","year":"2020","unstructured":"Kardoust Parizi, M. et al. Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. World J. Urol. 38, 1437\u20131449 (2020).","journal-title":"World J. Urol."},{"key":"1179_CR31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s00345-024-05192-x","volume":"42","author":"A Guigui","year":"2024","unstructured":"Guigui, A. et al. Prognostic significance of residual tumor at restaging transurethral bladder resection in high-risk non-muscle-invasive bladder cancer. World J. Urol. 42, 480 (2024).","journal-title":"World J. Urol."},{"key":"1179_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12957-018-1310-0","volume":"16","author":"P Zapa\u0142a","year":"2018","unstructured":"Zapa\u0142a, P. et al. Clinical rationale and safety of restaging transurethral resection in indication-stratified patients with high-risk non-muscle-invasive bladder cancer. World J. Surg. Oncol. 16, 6 (2018).","journal-title":"World J. Surg. Oncol."},{"key":"1179_CR33","first-page":"CD013776","volume":"12","author":"P Maisch","year":"2021","unstructured":"Maisch, P. et al. Blue versus white light for transurethral resection of non-muscle invasive bladder cancer. Cochrane Database Syst. Rev. 12, CD013776 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1179_CR34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.eururo.2025.05.035","volume":"88","author":"SS Chang","year":"2025","unstructured":"Chang, S. S. et al. Computational histology artificial intelligence (CHAI) enhances risk stratification of high-grade Ta non-muscle-invasive bladder cancer in a multicenter cohort: comparison to current European Association of Urology and American Urological Association stratification schemes. Eur. Urol. 88, 411\u2013413 (2025).","journal-title":"Eur. Urol."},{"key":"1179_CR35","first-page":"192","volume":"213","author":"Y Lotan","year":"2025","unstructured":"Lotan, Y. et al. Predicting response to intravesical bacillus calmette-gu\u00e9rin in high-risk nonmuscle-invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12-center cohort. J. Urol. 213, 192\u2013204 (2025).","journal-title":"J. Urol."},{"key":"1179_CR36","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.euo.2025.04.006","volume":"8","author":"VT Packiam","year":"2025","unstructured":"Packiam, V. T. et al. Presence of an artificial intelligence-powered predictive biomarker is associated with a poor response to intravesical Bacillus Calmette\u2013Guerin but not to intravesical sequential gemcitabine\/docetaxel in patients with high-grade non-muscle-invasive bladder cancer. Eur. Urol. Oncol. 8, 1461\u20131465 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1179_CR37","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.euo.2023.10.003","volume":"7","author":"X Tan","year":"2024","unstructured":"Tan, X. et al. Prognostic significance of HER2 expression in patients with Bacillus Calmette\u2013Gu\u00e9rin-exposed non-muscle-invasive bladder cancer. Eur. Urol. Oncol. 7, 760\u2013769 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1179_CR38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein, J. M. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline: 2024 amendment. J. Urol. 211, 533\u2013538 (2024).","journal-title":"J. Urol."},{"key":"1179_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk, M. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur. Urol. 81, 75\u201394 (2022).","journal-title":"Eur. Urol."},{"key":"1179_CR40","doi-asserted-by":"publisher","first-page":"27.e1","DOI":"10.1016\/j.urolonc.2012.09.011","volume":"32","author":"FA Yafi","year":"2014","unstructured":"Yafi, F. A. et al. Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer. Urol. Oncol. 32, 27.e1\u20136 (2014).","journal-title":"Urol. Oncol."},{"key":"1179_CR41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/bju.14574","volume":"124","author":"Y Freifeld","year":"2019","unstructured":"Freifeld, Y. & Lotan, Y. Effect of blue-light cystoscopy on contemporary performance of urine cytology. BJU Int. 124, 251\u2013257 (2019).","journal-title":"BJU Int."},{"key":"1179_CR42","unstructured":"Rosenthal, D., Wojcik E. M., Kurtycz, D. & VandenBussche, C. The Paris System for Reporting Urinary Cytology 2nd edn (Springer Nature, 2022)."},{"key":"1179_CR43","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.eururo.2006.10.044","volume":"51","author":"PMJ Moonen","year":"2007","unstructured":"Moonen, P. M. J. et al. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur. Urol. 51, 1275\u20131280 (2007).","journal-title":"Eur. Urol."},{"key":"1179_CR44","doi-asserted-by":"publisher","first-page":"108.e19","DOI":"10.1016\/j.urolonc.2021.11.013","volume":"40","author":"F Pierconti","year":"2022","unstructured":"Pierconti, F. et al. The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma. Urol. Oncol. 40, 108.e19\u2013108.e25 (2022).","journal-title":"Urol. Oncol."},{"key":"1179_CR45","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.eururo.2019.04.035","volume":"76","author":"B Konety","year":"2019","unstructured":"Konety, B. et al. Evaluation of CxBladder and adjudication of atypical cytology and equivocal cystoscopy. Eur. Urol. 76, 238\u2013243 (2019).","journal-title":"Eur. Urol."},{"key":"1179_CR46","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1464-410X.2010.10026.x","volume":"108","author":"AM Kamat","year":"2011","unstructured":"Kamat, A. M. et al. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int. 108, 1119\u20131123 (2011).","journal-title":"BJU Int."},{"key":"1179_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.eururo.2025.03.018","volume":"88","author":"T Dreyer","year":"2025","unstructured":"Dreyer, T. et al. Use of the Xpert bladder cancer monitor urinary biomarker test for guiding cystoscopy in high-grade non-muscle-invasive bladder cancer: results from the randomized controlled DaBlaCa-15 trial. Eur. Urol. 88, 23\u201330 (2025).","journal-title":"Eur. Urol."},{"key":"1179_CR48","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.euo.2025.04.020","volume":"8","author":"BJ Schmitz-Dr\u00e4ger","year":"2025","unstructured":"Schmitz-Dr\u00e4ger, B. J. et al. Results of the prospective randomized urofollow trial comparing marker-guided versus cystoscopy-based surveillance in patients with low\/intermediate-risk bladder cancer. Eur. Urol. Oncol. 8, 1041\u20131049 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1179_CR49","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.juro.2011.10.144","volume":"187","author":"AM Kamat","year":"2012","unstructured":"Kamat, A. M. et al. Use of fluorescence in situ hybridization to predict response to Bacillus Calmette\u2013Gu\u00e9rin therapy for bladder cancer: results of a prospective trial. J. Urol. 187, 862\u2013867 (2012).","journal-title":"J. Urol."},{"key":"1179_CR50","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/JU.0000000000000355","volume":"202","author":"Y Lotan","year":"2019","unstructured":"Lotan, Y. et al. Evaluation of the fluorescence in situ hybridization test to predict recurrence and\/or progression of disease after Bacillus Calmette\u2013Gu\u00e9rin for primary high grade nonmuscle invasive bladder cancer: results from a prospective multicenter trial. J. Urol. 202, 920\u2013926 (2019).","journal-title":"J. Urol."},{"key":"1179_CR51","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2025.03.023","volume":"88","author":"M-P St-Laurent","year":"2025","unstructured":"St-Laurent, M.-P. et al. Urine tumor DNA to stratify the risk of recurrence in patients treated with atezolizumab for bacillus calmette-gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer. Eur. Urol. 88, 430\u2013434 (2025).","journal-title":"Eur. Urol."},{"key":"1179_CR52","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.euo.2025.05.019","volume":"8","author":"B Wang","year":"2025","unstructured":"Wang, B., Davis, L. E., Weight, C. J., Abouassaly, R. & Bukavina, L. Real-world experience with a commercial circulating tumor DNA assay in non-muscle-invasive bladder cancer. Eur. Urol. Oncol. 8, 883\u2013887 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1179_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000005034","author":"R Ben-David","year":"2026","unstructured":"Ben-David, R. et al. Preoperative ctDNA predicts upstaging and recurrence in high-risk non-muscle-invasive bladder cancer undergoing radical cystectomy. J. Urol. https:\/\/doi.org\/10.1097\/JU.0000000000005034 (2026).","journal-title":"J. Urol."},{"key":"1179_CR54","unstructured":"Bladder Cancer (Version 2.2026) (National Comprehensive Cancer Network, 2026)."},{"key":"1179_CR55","doi-asserted-by":"publisher","first-page":"S1763","DOI":"10.1016\/j.annonc.2025.09.124","volume":"36","author":"C Vulsteke","year":"2025","unstructured":"Vulsteke, C. et al. LBA2 perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study. Ann. Oncol. 36, S1763 (2025).","journal-title":"Ann. Oncol."},{"key":"1179_CR56","doi-asserted-by":"publisher","first-page":"LBA630","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630","volume":"44","author":"MD Galsky","year":"2026","unstructured":"Galsky, M. D. et al. Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label, phase 3 KEYNOTE-B15 study. J. Clin. Oncol. 44, LBA630 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR57","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.euo.2024.01.014","volume":"7","author":"R Kool","year":"2024","unstructured":"Kool, R. et al. Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: an inverse probability treatment weighted analysis. Eur. Urol. Oncol. 7, 1350\u20131357 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1179_CR58","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3390\/cancers15041323","volume":"15","author":"HW Lee","year":"2023","unstructured":"Lee, H. W., Kwon, W.-A., Nguyen, L. N. T., Phan, D. T. T. & Seo, H. K. Approaches to clinical complete response after neoadjuvant chemotherapy in muscle-invasive bladder cancer: possibilities and limitations. Cancers 15, 1323 (2023).","journal-title":"Cancers"},{"key":"1179_CR59","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","volume":"2","author":"D Liu","year":"2016","unstructured":"Liu, D. et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol. 2, 1094\u20131096 (2016).","journal-title":"JAMA Oncol."},{"key":"1179_CR60","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00287","volume":"8","author":"G Iyer","year":"2024","unstructured":"Iyer, G. et al. DNA damage response alterations predict for neoadjuvant chemotherapy sensitivity in muscle-invasive bladder cancer: a correlative analysis of the SWOG S1314 Trial. JCO Precis. Oncol. 8, e2400287 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"1179_CR61","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3390\/cancers14071692","volume":"14","author":"G Sj\u00f6dahl","year":"2022","unstructured":"Sj\u00f6dahl, G. et al. Molecular subtypes as a basis for stratified use of neoadjuvant chemotherapy for muscle-invasive bladder cancer-a narrative review. Cancers 14, 1692 (2022).","journal-title":"Cancers"},{"key":"1179_CR62","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","volume":"27","author":"TW Flaig","year":"2021","unstructured":"Flaig, T. W. et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin. Cancer Res. 27, 2435\u20132441 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1179_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.12363","volume":"10","author":"J Griffin","year":"2024","unstructured":"Griffin, J. et al. Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. J. Pathol. Clin. Res. 10, e12363 (2024).","journal-title":"J. Pathol. Clin. Res."},{"key":"1179_CR64","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t, L. et al. Bladder cancer. Nat. Rev. Dis. Primers 9, 58 (2023).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1179_CR65","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta, A. R. et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 24, 669\u2013681 (2023).","journal-title":"Lancet Oncol."},{"key":"1179_CR66","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","volume":"36","author":"O Fahmy","year":"2018","unstructured":"Fahmy, O. et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol. Oncol. 36, 43\u201353 (2018).","journal-title":"Urol. Oncol."},{"key":"1179_CR67","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1200\/JCO-24-01214","volume":"43","author":"D Geynisman","year":"2025","unstructured":"Geynisman, D. et al. A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER). J. Clin. Oncol. 43, 1113\u20131122 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR68","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.euo.2022.04.008","volume":"5","author":"PJ Hensley","year":"2022","unstructured":"Hensley, P. J. et al. Contemporary staging for muscle-invasive bladder cancer: accuracy and limitations. Eur. Urol. Oncol. 5, 403\u2013411 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"1179_CR69","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","volume":"29","author":"SV Lindskrog","year":"2023","unstructured":"Lindskrog, S. V. et al. Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up. Clin. Cancer Res. 29, 4797\u20134807 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1179_CR70","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen, E. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol. 37, 1547\u20131557 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 7","key":"1179_CR71","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1200\/JCO.2026.44.7_suppl.636","volume":"44","author":"MS Van der Heijden","year":"2026","unstructured":"Van der Heijden, M. S. & Powles, T. Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA. J. Clin. Oncol. 44 (Suppl. 7), 636 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR72","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102\u20132114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR73","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo, A. B. et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 392, 45\u201355 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR74","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euo.2023.05.012","volume":"7","author":"E Crupi","year":"2024","unstructured":"Crupi, E. et al. Circulating tumor DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: a systematic review. Eur. Urol. Oncol. 7, 44\u201352 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1179_CR75","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.euo.2025.04.027","volume":"8","author":"A Eraky","year":"2025","unstructured":"Eraky, A. et al. Bladder cancer with undetectable circulating tumor DNA after radical cystectomy may be amenable to a less intense imaging surveillance protocol: a diagnostic accuracy study. Eur. Urol. Oncol. 8, 1505\u20131512 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1179_CR76","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","volume":"37","author":"M Galsky","year":"2026","unstructured":"Galsky, M. et al. Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. Ann. Oncol. 37, 69\u201378 (2026).","journal-title":"Ann. Oncol."},{"key":"1179_CR77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511885","author":"T Powles","year":"2025","unstructured":"Powles, T. et al. ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2511885 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR78","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.annonc.2025.12.018","volume":"37","author":"L Dyrskj\u00f8t","year":"2026","unstructured":"Dyrskj\u00f8t, L. et al. ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial. Ann. Oncol. 37, 712\u2013724 (2026).","journal-title":"Ann. Oncol."},{"key":"1179_CR79","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05987241 (2026)."},{"key":"1179_CR80","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.urolonc.2019.05.021","volume":"37","author":"T Iwata","year":"2019","unstructured":"Iwata, T. et al. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: a systematic review. Urol. Oncol. 37, 659\u2013671 (2019).","journal-title":"Urol. Oncol."},{"key":"1179_CR81","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1200\/JCO.2016.69.6120","volume":"35","author":"F Kastrinos","year":"2017","unstructured":"Kastrinos, F. et al. Development and validation of the PREMM5 model for comprehensive risk assessment of Lynch syndrome. J. Clin. Oncol. 35, 2165\u20132172 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR82","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0016-5085(99)70510-X","volume":"116","author":"HF Vasen","year":"1999","unstructured":"Vasen, H. F., Watson, P., Mecklin, J. P. & Lynch, H. T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116, 1453\u20131456 (1999).","journal-title":"Gastroenterology"},{"key":"1179_CR83","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N. Engl. J. Med. 384, 1125\u20131135 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR84","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot, Y. et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 389, 1961\u20131971 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR85","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","volume":"393","author":"X Sheng","year":"2025","unstructured":"Sheng, X. et al. Disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial cancer. N. Engl. J. Med. 393, 2324\u20132337 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR86","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","volume":"18","author":"S Sun","year":"2025","unstructured":"Sun, S. et al. The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives. J. Hematol. Oncol. 18, 84 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"1179_CR87","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00121","volume":"6","author":"RP Graf","year":"2022","unstructured":"Graf, R. P. et al. Tumor mutational burden as a predictor of first-line immune checkpoint inhibitor versus carboplatin benefit in cisplatin-unfit patients with urothelial carcinoma. JCO Precis. Oncol. 6, e2200121 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"1179_CR88","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"TA Chan","year":"2019","unstructured":"Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44\u201356 (2019).","journal-title":"Ann. Oncol."},{"key":"1179_CR89","doi-asserted-by":"publisher","first-page":"e010311","DOI":"10.1136\/jitc-2024-010311","volume":"13","author":"DR Gandara","year":"2025","unstructured":"Gandara, D. R. et al. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J. Immunother. Cancer 13, e010311 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1179_CR90","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"1179_CR91","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","volume":"35","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities. Ann. Oncol. 35, 508\u2013522 (2024).","journal-title":"Ann. Oncol."},{"key":"1179_CR92","doi-asserted-by":"publisher","first-page":"e000335","DOI":"10.1136\/bmjonc-2024-000335","volume":"3","author":"EBA Chandran","year":"2024","unstructured":"Chandran, E. B. A. et al. Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis. BMJ Oncol. 3, e000335 (2024).","journal-title":"BMJ Oncol."},{"key":"1179_CR93","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","volume":"392","author":"A Cercek","year":"2025","unstructured":"Cercek, A. et al. Nonoperative management of mismatch repair-deficient tumors. N. Engl. J. Med. 392, 2297\u20132308 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR94","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.eururo.2022.10.020","volume":"83","author":"F Erlmeier","year":"2023","unstructured":"Erlmeier, F. et al. Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition. Eur. Urol. 83, 133\u2013142 (2023).","journal-title":"Eur. Urol."},{"key":"1179_CR95","doi-asserted-by":"publisher","first-page":"e005573","DOI":"10.1136\/jitc-2022-005573","volume":"10","author":"JG Maule","year":"2022","unstructured":"Maule, J. G. et al. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. J. Immunother. Cancer 10, e005573 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1179_CR96","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejca.2018.11.007","volume":"106","author":"M Eckstein","year":"2019","unstructured":"Eckstein, M. et al. Performance of the food and drug administration\/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur. J. Cancer 106, 234\u2013243 (2019).","journal-title":"Eur. J. Cancer"},{"key":"1179_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954910","volume":"13","author":"E Munari","year":"2022","unstructured":"Munari, E. et al. Comparison of three validated PD-L1 immunohistochemical assays in urothelial carcinoma of the bladder: interchangeability and issues related to patient selection. Front. Immunol. 13, 954910 (2022).","journal-title":"Front. Immunol."},{"key":"1179_CR98","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/modpathol.2017.188","volume":"31","author":"M Tretiakova","year":"2018","unstructured":"Tretiakova, M. et al. Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. Mod. Pathol. 31, 623\u2013632 (2018).","journal-title":"Mod. Pathol."},{"key":"1179_CR99","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.1215","volume":"7","author":"BA Maiorano","year":"2024","unstructured":"Maiorano, B. A. et al. Significance of PD-L1 in metastatic urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Netw. Open. 7, e241215 (2024).","journal-title":"JAMA Netw. Open."},{"key":"1179_CR100","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","volume":"16","author":"K Pantel","year":"2019","unstructured":"Pantel, K. & Alix-Panabi\u00e8res, C. Liquid biopsy and minimal residual disease \u2013 latest advances and implications for cure. Nat. Rev. Clin. Oncol. 16, 409\u2013424 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1179_CR101","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 931\u2013945 (2021).","journal-title":"Lancet Oncol."},{"key":"1179_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37568-9","volume":"14","author":"AG Robertson","year":"2023","unstructured":"Robertson, A. G. et al. Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nat. Commun. 14, 2126 (2023).","journal-title":"Nat. Commun."},{"key":"1179_CR103","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25\u201341 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"1179_CR104","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.euf.2017.08.002","volume":"5","author":"A Necchi","year":"2019","unstructured":"Necchi, A. et al. Comparison of fibroblast growth-factor receptor gene alterations at the DNA versus messenger RNA level in advanced urothelial cancer: insights for clinical research. Eur. Urol. Focus. 5, 689\u2013692 (2019).","journal-title":"Eur. Urol. Focus."},{"key":"1179_CR105","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2217\/fon-2016-0042","volume":"12","author":"E di Martino","year":"2016","unstructured":"di Martino, E., Tomlinson, D. C., Williams, S. V. & Knowles, M. A. A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncol. 12, 2243\u20132263 (2016).","journal-title":"Future Oncol."},{"key":"1179_CR106","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamaoncol.2022.1167","volume":"8","author":"V Nimgaonkar","year":"2022","unstructured":"Nimgaonkar, V., Hubbard, R. A., Carpenter, E. L. & Mamtani, R. Biomarker testing, treatment uptake, and survival among patients with urothelial cancer receiving gene-targeted therapy. JAMA Oncol. 8, 1070\u20131072 (2022).","journal-title":"JAMA Oncol."},{"key":"1179_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102091","volume":"22","author":"V Tateo","year":"2024","unstructured":"Tateo, V. et al. Optimizing the use of next-generation sequencing assays in patients with urothelial carcinoma: recommendations by the 2023 san raffaele retreat panel. Clin. Genitourin. Cancer 22, 102091 (2024).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1179_CR108","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/JCO.2025.43.5_suppl.662","volume":"43","author":"G Iyer","year":"2025","unstructured":"Iyer, G. et al. A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1. J. Clin. Oncol. 43, 662 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR109","doi-asserted-by":"publisher","first-page":"S1137","DOI":"10.1016\/j.annonc.2024.08.2051","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. 1966MO EV-302: exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la\/mUC). Ann. Oncol. 35, S1137\u2013S1138 (2024).","journal-title":"Ann. Oncol."},{"key":"1179_CR110","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00470","volume":"8","author":"E Crupi","year":"2024","unstructured":"Crupi, E. et al. Nectin-4 positivity in genitourinary malignancies: a systematic review. JCO Precis. Oncol. 8, e2400470 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"1179_CR111","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","volume":"42","author":"N Kl\u00fcmper","year":"2024","unstructured":"Kl\u00fcmper, N. et al. NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer. J. Clin. Oncol. 42, 2446\u20132455 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR112","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1200\/JCO.2026.44.7_suppl.854","volume":"44","author":"N Kl\u00fcmper","year":"2026","unstructured":"Kl\u00fcmper, N. et al. Membranous Nectin-4 expression to predict enfortumab vedotin response in metastatic urothelial carcinoma. J. Clin. Oncol. 44, 854\u2013854 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR113","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bju.16643","volume":"136","author":"C Olah","year":"2025","unstructured":"Olah, C. et al. Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer. BJU Int. 136, 297\u2013305 (2025).","journal-title":"BJU Int."},{"key":"1179_CR114","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00879","volume":"9","author":"VS Koshkin","year":"2025","unstructured":"Koshkin, V. S. et al. Testing and interpretation of human epidermal growth factor receptor 2 protein expression and ERBB2 gene amplification in advanced urothelial carcinoma. JCO Precis. Oncol. 9, e2400879 (2025).","journal-title":"JCO Precis. Oncol."},{"key":"1179_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67643-2","volume":"17","author":"Z Chen","year":"2025","unstructured":"Chen, Z. et al. Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer. Nat. Commun. 17, 919 (2025).","journal-title":"Nat. Commun."},{"key":"1179_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-025-01075-x","author":"D Raggi","year":"2025","unstructured":"Raggi, D. et al. HER2 and urothelial carcinoma: current understanding and future directions. Nat. Rev. Urol. https:\/\/doi.org\/10.1038\/s41585-025-01075-x (2025).","journal-title":"Nat. Rev. Urol."},{"key":"1179_CR117","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","volume":"52","author":"M Hofmann","year":"2008","unstructured":"Hofmann, M. et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52, 797\u2013805 (2008).","journal-title":"Histopathology"},{"key":"1179_CR118","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng, X. et al. Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J. Clin. Oncol. 42, 1391\u20131402 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR119","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR120","doi-asserted-by":"publisher","first-page":"S1138","DOI":"10.1016\/j.annonc.2024.08.2052","volume":"35","author":"MD Galsky","year":"2024","unstructured":"Galsky, M. D. et al. 1967MO preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la\/mUC): RC48G001 cohort C. Ann. Oncol. 35, S1138\u2013S1139 (2024).","journal-title":"Ann. Oncol."},{"key":"1179_CR121","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","volume":"36","author":"L Zhou","year":"2025","unstructured":"Zhou, L. et al. Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study. Ann. Oncol. 36, 331\u2013339 (2025).","journal-title":"Ann. Oncol."},{"key":"1179_CR122","doi-asserted-by":"publisher","first-page":"LBA631","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA631","volume":"44","author":"T Powles","year":"2026","unstructured":"Powles, T. et al. RC48G001: a phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC. J. Clin. Oncol. 44, LBA631\u2013LBA631 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1179_CR123","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng, X. et al. Open-label, multicenter, phase II Study of RC48-ADC, a HER2-targeting antibody\u2013drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin. Cancer Res. 27, 43\u201351 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1179_CR124","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","volume":"27","author":"CE Chu","year":"2021","unstructured":"Chu, C. E. et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin. Cancer Res. 27, 5123\u20135130 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1179_CR125","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/his.15130","volume":"84","author":"V Bahlinger","year":"2024","unstructured":"Bahlinger, V. et al. Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts. Histopathology 84, 863\u2013876 (2024).","journal-title":"Histopathology"},{"key":"1179_CR126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1432586","volume":"15","author":"J Li","year":"2024","unstructured":"Li, J. et al. The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer. Front. Immunol. 15, 1432586 (2024).","journal-title":"Front. Immunol."},{"key":"1179_CR127","first-page":"384","volume":"9","author":"T Pan","year":"2021","unstructured":"Pan, T., Lehman, E. & Raman, J. D. Performance characteristics of urinary cytology in patients presenting with gross and microscopic hematuria. Am. J. Clin. Exp. Urol. 9, 384\u2013389 (2021).","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"1179_CR128","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/0006-291X(85)91893-5","volume":"132","author":"MA Cassatella","year":"1985","unstructured":"Cassatella, M. A., Della Bianca, V., Berton, G. & Rossi, F. Activation by gamma interferon of human macrophage capability to produce toxic oxygen molecules is accompanied by decreased Km of the superoxide-generating NADPH oxidase. Biochem. Biophys. Res. Commun. 132, 908\u2013914 (1985).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1179_CR129","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/JU.0000000000000786","volume":"204","author":"KEM van Kessel","year":"2020","unstructured":"van Kessel, K. E. M. et al. A urine based genomic assay to triage patients with hematuria for cystoscopy. J. Urol. 204, 50\u201357 (2020).","journal-title":"J. Urol."},{"key":"1179_CR130","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.juro.2016.09.118","volume":"197","author":"KEM van Kessel","year":"2017","unstructured":"van Kessel, K. E. M. et al. Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy. J. Urol. 197, 590\u2013595 (2017).","journal-title":"J. Urol."},{"key":"1179_CR131","doi-asserted-by":"publisher","first-page":"E347","DOI":"10.5489\/cuaj.1668","volume":"8","author":"A Guo","year":"2014","unstructured":"Guo, A. et al. Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: a meta-analysis. Can. Urol. Assoc. J. 8, E347\u2013E352 (2014).","journal-title":"Can. Urol. Assoc. J."},{"key":"1179_CR132","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0022-5347(01)61918-9","volume":"161","author":"D Pode","year":"1999","unstructured":"Pode, D. et al. Noninvasive detection of bladder cancer with the BTA stat test. J. Urol. 161, 443\u2013446 (1999).","journal-title":"J. Urol."},{"key":"1179_CR133","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3390\/diagnostics14182061","volume":"14","author":"JC Harvey","year":"2024","unstructured":"Harvey, J. C. et al. Analytical validation of Cxbladder\u00ae Detect, Triage, and Monitor: assays for detection and management of urothelial carcinoma. Diagnostics 14, 2061 (2024).","journal-title":"Diagnostics"},{"key":"1179_CR134","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jmoldx.2024.04.001","volume":"26","author":"B-R Bang","year":"2024","unstructured":"Bang, B.-R. et al. EarlyTect BCD, a streamlined PENK methylation test in urine DNA, effectively detects bladder cancer in patients with hematuria. J. Mol. Diagn. 26, 613\u2013623 (2024).","journal-title":"J. Mol. Diagn."},{"key":"1179_CR135","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4111\/kju.2010.51.2.88","volume":"51","author":"HS Choi","year":"2010","unstructured":"Choi, H. S., Lee, S. I., Kim, D. J. & Jeong, T. Y. Usefulness of the NMP22BladderChek test for screening and follow-up of bladder cancer. Korean J. Urol. 51, 88\u201393 (2010).","journal-title":"Korean J. Urol."},{"key":"1179_CR136","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.urology.2010.04.059","volume":"77","author":"EC Hwang","year":"2011","unstructured":"Hwang, E. C. et al. Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study. Urology 77, 154\u2013159 (2011).","journal-title":"Urology"},{"key":"1179_CR137","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.18632\/oncotarget.22065","volume":"8","author":"Z Wang","year":"2017","unstructured":"Wang, Z. et al. Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis. Oncotarget 8, 100648\u2013100656 (2017).","journal-title":"Oncotarget"},{"key":"1179_CR138","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1464-410X.2011.10664.x","volume":"110","author":"CGT Blick","year":"2012","unstructured":"Blick, C. G. T. et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int. 110, 84\u201394 (2012).","journal-title":"BJU Int."},{"key":"1179_CR139","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cncy.21327","volume":"121","author":"H Dimashkieh","year":"2013","unstructured":"Dimashkieh, H. et al. Evaluation of UroVysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. 121, 591\u2013597 (2013).","journal-title":"Cancer Cytopathol."},{"key":"1179_CR140","doi-asserted-by":"publisher","first-page":"839598","DOI":"10.3389\/fgene.2022.839598","volume":"13","author":"N Kavcic","year":"2022","unstructured":"Kavcic, N., Peric, I., Zagorac, A. & Kokalj Vokac, N. Clinical evaluation of two non-invasive genetic tests for detection and monitoring of urothelial carcinoma: validation of UroVysion and Xpert bladder cancer detection test. Front. Genet. 13, 839598 (2022).","journal-title":"Front. Genet."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01179-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01179-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01179-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:03:12Z","timestamp":1785992592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01179-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":140,"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01179-y","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"22 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.J.H. has acted as adviser\/consultant for Ferring, ImmunityBio, Johnson & Johnson and UroGen Pharma. R.L. has received research support from Predicine, Valar Labs and Johnson & Johnson; has acted as adviser\/consultant for BMS, Merck, CG Oncology, ImmunityBio, Pfizer, Johnson & Johnson, AstraZeneca, enGene, Ferring and Valar Labs; has received honoraria from UroToday, IBCG, MashUP Media and MJH Lifesciences; and has received travel support from Predicine, CG Oncology and Johnson & Johnson. S.G. has acted as consultant for AstraZeneca, Natera, BMS, Merck, Bayer, Foundation Medicine, Gilead Sciences, Pfizer and Novartis; has been a speaker for BMS; and received research funding from Novartis, Exelixis, Merck, BMS, Tyra Biosciences, Flare Therapeutics and Roche. L.B. has acted as consultant for Charit\u00e9, ImmunityBio, Ferring Pharmaceuticals, Pfizer, Aura Biosciences, Merck and Janssen; has received honoraria from Johnson & Johnson Clinical Immersion Program and PeerView Bladder Cancer Symposium; has stock options from Tempus AI; and has been on the Editorial Board for\n                      European Urology\n                      and\n                      Urology Times\n                      . K.W.M. has acted as an adviser\/ consultant for EMD Serono, Pfizer, UroGen, Riva Therapeutics, Natera and Astellas; has received research support from Pfizer and Novo Ventures; has equity in Riva Therapeutics and Illudent Therapeutics; has received writer\/speaking fees from UpToDate and OncLive; has patents filed for mutational signatures of DNA repair deficiency; has a leadership role in the International Bladder Cancer Network; and is an editorial board member at Science Advances. W.S.T. has served as consultant\/adviser to Ferring. P.A. has served as consultant\/speaker for Urogen and Ferring; and consultant for ImmunityBio. H.A.A. has consulted for AstraZeneca, Paige.AI, Pfizer and Janssen. T.J.B. has received honoraria from Ferring, Janssen and UroGen; and served as consultant\/adviser to UroGen Pharma. T.W.F. has leadership positions in Aurora Oncology, University of Colorado\/UC Health and CPC\u2014Clinical Research and Community Health; holds stock or ownership in Aurora Oncology; has received research funding from Novartis, Bavarian Nordic, Dendreon, GTx, Janssen Oncology, Medivation, Sanofi, Pfizer, Bristol Myers Squibb, Roche\/Genentech, Exelixis, Aragon Pharmaceuticals, SOTIO, Tokai Pharmaceuticals, AstraZeneca\/MedImmune, Lilly, Astellas Pharma, Agensys, Seagen, La Roche-Posay, Merck, Myovant Sciences and Criterium; and has two patents with The University of Colorado related to early-stage bladder cancer treatment and detection (neither is commercialized or in active clinical development currently). W.K. has acted as consultant\/adviser for Ferring, AstraZeneca, Merck, Janssen, Bayer, Pfizer, EMD Serono, Photocure, CG Oncology, enGene, Knighttx and Accord. M.R.K. has a consulting or advisory role for Nanology, UroGen Pharma, Pfizer, Johnson & Johnson\/Janssen, Aura Biosciences and ImmunityBio. B.R.K. has served as a consultant\/ adviser for Valar Labs, Photocure, Asieris Pharmaceuticals, Ferring Pharmaceuticals, Illumina and Abbott; and has ownership\/investment interest in Astrin Biosciences and Styx Biotechnologies. J.B.K. has served as consultant\/adviser to Intuitive Surgical. Y.L. has acted as consultant\/adviser for Photocure, AstraZeneca, Merck, Fergene, Nucleix, Ambu, Seattle Genetics, Virtuoso Surgical, Stimit, Urogen, Vessi Medical, CAPs Medical, Nonagen, Aura Biosciences, Convergent Genomics, Pacific Edge, Pfizer, Phinomics, CG Oncology, Uroviu, Promis Diagnostics, Valar Labs, Uroessentials, NRx Pharmaceuticals, Vesica Health, Janssen, ImmunityBio, Trigone Pharma and Relmada; and has stock\/stock options in Vessi, CAPs Medical, Relmada, Phinomics, Uroviu, Valar Labs, Vesica Health and Trigone Pharma. D.J.M. reports consulting roles for CG Oncology and Owkin; research support from Janssen and Convergent Genomics; leadership roles for SWOG GU Committee and the Bladder Cancer Advocacy Network scientific advisory board; and an inventor interest in pending patent PCT\/US2022\/019757 on the use of B8T as a prognostic and predictive biomarker in cancer. L.S.M. has acted as consultant for Johnson & Johnson and Merck. M.M. has acted as an adviser for Photocure, Janssen, Medac and Pfizer. A.N. reports institutional research funding from AstraZeneca and Merck Sharp & Dohme; grants\/contracts from Bristol Myers Squibb, Gilead Sciences and Ipsen; consulting\/advisory fees from Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Clovis Oncology, Daiichi-Sankyo, F. Hoffman-La Roche, Ferring, Gilead Sciences, GlaxoSmithKline, Incyte, Janssen Cilag EMA, Merck Sharp & Dohme, Rainier Therapeutics, Roche and Seattle Genetics\/Astellas; honoraria from AstraZeneca, Bristol Myers Squibb, Foundation Medicine, Janssen, Merck and Roche; support for other professional activities from Bayer; support for travel from AstraZeneca, Janssen, Merck Sharp & Dohme, Rainier Therapeutics and Roche; and stock and other ownership interests in Bayer outside the submitted work. K.O. has served on consulting or advisory boards for Roche, MSD, Pfizer, Janssen, Astellas, AstraZeneca, Mylan, Ipsen, Novartis, Hikma, Sothema and SunPharma; has received research funding from Roche. V.T.P. serves as a consultant\/speaker for Valar Labs, Veracyte, Photocure, Ferring and Johnson & Johnson; and has a joint provisional patent related to the DRIFT device. B.S. reports relationships with Ferring, Janssen, ImmunityBio and Urogen Pharma. R.J.B. received honoraria from Tersera, Knight, Astellas and Tolmar. A.M.K. has received research funding from FKD Therapies (now Ferring), the Patient-Centered Outcomes Research Institute (PCORI), Photocure, Seagen, EnGene, Arquer Diagnostics and SWOG; has acted as adviser\/consultant for Astellas Pharma, Biological Dynamics, Bristol Myers Squibb, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Genentech, Imagin Medical, ImmunityBio, Imvax, Incyte, Janssen, Medac, Merck, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Sesen Bio (now Carisma), Theralase, Urogen Pharma, US Biotest, Valar Labs and Vivet Therapeutics; holds a joint patent with MD Anderson Cancer Center for CyPRIT (Cytokine Predictors of Response to Intravesical Therapy); and has held a leadership role in the International Bladder Cancer Group (IBCG),\n                      European Urology Oncology\n                      , the\n                      Journal of Urology\n                      , UroToday, American Urological Association (AUA) and World Bladder Cancer Patient Coalition. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}